Q1 EPS Estimates for USANA Health Sciences Cut by Sidoti Csr

USANA Health Sciences, Inc. (NYSE:USNA) – Stock analysts at Sidoti Csr dropped their Q1 2025 earnings per share estimates for USANA Health Sciences in a research report issued to clients and investors on Wednesday, February 26th. Sidoti Csr analyst A. Lebiedzinski now expects that the company will post earnings per share of $0.71 for the quarter, down from their prior forecast of $0.77. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q2 2025 earnings at $0.60 EPS, Q4 2025 earnings at $0.71 EPS, FY2025 earnings at $2.75 EPS, Q2 2026 earnings at $0.81 EPS and Q4 2026 earnings at $0.92 EPS.

A number of other equities analysts have also recently issued reports on USNA. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th. DA Davidson reduced their target price on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday. Finally, Sidoti cut USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th.

USANA Health Sciences Trading Up 3.2 %

Shares of USNA opened at $29.55 on Thursday. USANA Health Sciences has a 1 year low of $27.71 and a 1 year high of $50.32. The stock has a market cap of $563.22 million, a P/E ratio of 10.44, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87. The stock’s 50-day moving average price is $33.50 and its two-hundred day moving average price is $36.56.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. The firm had revenue of $213.61 million during the quarter, compared to analyst estimates of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%.

Hedge Funds Weigh In On USANA Health Sciences

Several institutional investors have recently modified their holdings of USNA. Creative Planning bought a new position in shares of USANA Health Sciences during the 3rd quarter valued at about $394,000. Allspring Global Investments Holdings LLC lifted its holdings in shares of USANA Health Sciences by 14,068.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 38,821 shares of the company’s stock valued at $1,472,000 after purchasing an additional 38,547 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of USANA Health Sciences by 13.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 124,008 shares of the company’s stock valued at $4,702,000 after purchasing an additional 14,756 shares in the last quarter. Harbor Capital Advisors Inc. lifted its holdings in shares of USANA Health Sciences by 44.1% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 8,859 shares of the company’s stock valued at $336,000 after purchasing an additional 2,713 shares in the last quarter. Finally, KBC Group NV lifted its holdings in shares of USANA Health Sciences by 96.6% during the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after purchasing an additional 519 shares in the last quarter. Institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.